Arzimanoglou, A; Brandl, U; Cross, JH; Gil-Nagel, A; Lagae, L; Landmark, CJ; Specchio, N; ... The Cannabinoids International Experts Panel, .; + view all Arzimanoglou, A; Brandl, U; Cross, JH; Gil-Nagel, A; Lagae, L; Landmark, CJ; Specchio, N; Nabbout, R; Thiele, EA; Gubbay, O; The Cannabinoids International Experts Panel, .; - view fewer (2020) Epilepsy and cannabidiol: a guide to treatment. Epileptic Disorders , 22 (1) pp. 1-14. 10.1684/epd.2020.1141.

Preview

Text Cross_Epilepsy and cannabidiol. A guide to treatment_VoR.pdf - Published Version Download (374kB) | Preview

Abstract

The growing interest in cannabidiol (CBD), specifically a pure form of CBD, as a treatment for epilepsy, among other conditions, is reflected in recent changes in legislation in some countries. Although there has been much speculation about the therapeutic value of cannabis-based products as an anti-seizure treatment for some time, it is only within the last two years that Class I evidence has been available for a pure form of CBD, based on placebo-controlled RCTs for patients with Lennox-Gastaut syndrome and Dravet syndrome. However, just as we are beginning to understand the significance of CBD as a treatment for epilepsy, in recent years, a broad spectrum of products advertised to contain CBD has emerged on the market. The effects of these products are fundamentally dependent on the purity, preparation, and concentration of CBD and other components, and consensus and standardisation are severely lacking regarding their preparation, composition, usage and effectiveness. This review aims to provide information to neurologists and epileptologists on the therapeutic value of CBD products, principally a purified form, in routine practice for patients with intractable epilepsy.

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as CSVJSONXML

Downloads by country - last 12 months

Export as JSONCSVXML

Archive Staff Only

View Item